Latest News and Press Releases

Alumis Reports First Quarter 2025 Financial Results and Highlights Recent Achievements

Generated net FUROSCIX® revenue of $11.8 million in the first quarter of 2025 Formally launched FUROSCIX in second approved indication, Chronic Kidney Disease, in April 2025 Autoinjector on track...

Angelini Ventures joins top-tier investor syndicate Investment will fund Phase 1b studies evaluating Therini Bio’s lead candidate, THN391, for the treatment of Alzheimer’s Disease (AD) and Diabetic...

Therini Bio raised a $39M Series A financing, bringing the Series A total to $75M, from top-tier investors to commence THN391 Ph 1b AD and DME studies

IN8bio Presents Preclinical Data Highlighting Potential of INB-619 T Cell Engager (TCE) for Autoimmune Disease at ASGCT 2025

aTyr Pharma Advances ATYR0101 to IND Candidate Stage for Pulmonary Fibrosis

GRAND CAYMAN, Cayman Islands, May 13, 2025 (GLOBE NEWSWIRE) -- Silexion Therapeutics Corp. (NASDAQ: SLXN) (“Silexion” or the “Company”), a clinical-stage biotech company developing RNA interference...

Alumis Stockholders Approve Merger with ACELYRIN

Applied Pharmaceutical Innovation (API) appoints Dr. Launa Aspeslet as Chief Translational Officer to drive life sciences commercialization in Canada.

SOUTH SAN FRANCISCO, Calif., May 13, 2025 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., ("ALX Oncology" or the "Company") (Nasdaq: ALXO), a clinical-stage biotechnology company advancing a...